No Vaccine, No Cure

Editor's Note: This is the second of two articles that looks at the progression of AIDS research over the 20 years since its identification. The first part: M.E. Watanabe, "AIDS, 20 years later," The Scientist, 15[12]:1, June 11, 2001. Despite billions of dollars spent in research funds and a brief reprieve in Western nations after the introduction of multidrug therapy, AIDS continues to win its battle against humankind. First diagnosed 20 years ago, there are still no cures and no vaccines. Pre

Written byMyrna Watanabe
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

When first diagnosed in the United States, the disease mainly struck gay men, intravenous drug abusers, and those who had received tainted blood or blood products. Today, its targets have changed. AIDS thrives in poverty and among those who are disenfranchised. Increasingly, it is becoming a disease affecting women and children: worldwide, in 2000, 2.2 million of the 4.7 million new HIV infections were in women.1

In the United States, "it continues to disproportionately [strike] communities of color," says Helene Gayle, the outgoing director of the Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention. "Almost 70 percent of new HIV infections are among African Americans and Latinos." Moreover, the prevalence of AIDS in gay men in the United States is no longer declining, after years of decreasing. "It's not enough to tell people that this is AIDS and how you get it," says Karungari ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies